{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:01:50Z","timestamp":1792180910383,"version":"4.4.0"},"reference-count":45,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Psoriasis is a chronic inflammatory disease frequently associated with obesity and type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for T2DM and obesity, have demonstrated anti-inflammatory and immunomodulatory properties that may be relevant in psoriasis. However, individual GLP-1RAs differ substantially in their pharmacological characteristics and clinical effects. Our objective was to systematically review the available evidence on the effects of individual GLP-1RAs in patients with psoriasis. Methods: A systematic review was conducted according to PRISMA 2020 guidelines. PubMed and Scopus were searched up to April 2026 for studies evaluating GLP-1RAs in psoriasis. Case reports, case series, observational studies, and randomized controlled trials were included. Preclinical, clinical and safety outcomes were extracted and narratively synthesized. Results: Twenty-six studies met the inclusion criteria. Most involved patients with concomitant obesity and\/or T2DM. Overall, semaglutide, liraglutide, exenatide, and tirzepatide were associated with improvements in psoriasis severity, often accompanied by reductions in body weight, glycated haemoglobin, inflammatory markers, and cardiometabolic risk factors. Semaglutide and liraglutide showed the most consistent evidence of benefit. Experimental and clinical data also suggested direct immunomodulatory effects on pathways involved in psoriasis pathogenesis. However, paradoxical psoriasiform eruptions and psoriasis exacerbations were reported with some agents. The evidence base was limited by the predominance of case reports and small observational studies, substantial heterogeneity, and the limited availability of randomized controlled trials. Conclusions: Current evidence suggests that GLP-1RAs may improve both psoriatic disease activity and cardiometabolic outcomes, particularly in patients with obesity or T2DM. Nevertheless, potential differences among individual agents warrant further investigation in larger controlled studies.<\/jats:p>","DOI":"10.3390\/jcm15135126","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:41:01Z","timestamp":1782902461000},"page":"5126","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of GLP-1 Receptor Agonists on Psoriasis: An \u201cAgent-Specific\u201d Systematic Review of the Literature"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9826-6039","authenticated-orcid":false,"given":"Andrea","family":"Marani","sequence":"first","affiliation":[{"name":"Dermatologic Unit, Department of Surgery, AUSL Romagna, 47923 Rimini, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Neri","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0617-2815","authenticated-orcid":false,"given":"Edvige","family":"Morea","sequence":"additional","affiliation":[{"name":"Clinic of Dermatology, Department of Medicine and Aging Sciences, University G. d\u2019Annunzio, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9700-5542","authenticated-orcid":false,"given":"Davide","family":"Bertolla","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, 44124 Ferrara, Italy"},{"name":"Dermatology Unit, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1640-6609","authenticated-orcid":false,"given":"Giulio","family":"Gualdi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9163-9691","authenticated-orcid":false,"given":"Alessandro","family":"Borghi","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4848-3817","authenticated-orcid":false,"given":"Andrea","family":"Conti","sequence":"additional","affiliation":[{"name":"Dermatologic Unit, Department of Surgery, AUSL Romagna, 47923 Rimini, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1589-9672","authenticated-orcid":false,"given":"Paolo","family":"Amerio","sequence":"additional","affiliation":[{"name":"Clinic of Dermatology, Department of Medicine and Aging Sciences, University G. d\u2019Annunzio, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"ref_3","first-page":"467","article-title":"Psoriasis as a Systemic Disease","volume":"121","author":"Mrowietz","year":"2024","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00228-025-03898-4","article-title":"GLP-1 receptor agonists: Emerging therapeutic potential in psoriasis management\u2014Current evidence and future outlook","volume":"81","author":"Atiquzzaman","year":"2025","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/jdv.20694","article-title":"The effects of GLP-1RA on inflammatory skin diseases: A comprehensive review","volume":"39","author":"Paschou","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1159\/000455840","article-title":"Psoriasis and Obesity","volume":"232","author":"Jensen","year":"2016","journal-title":"Dermatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"ref_9","unstructured":"Latif, W., Lambrinos, K.J., Patel, P., and Rodriguez, R. (2026). Compare and Contrast the Glucagon-like Peptide-1 Receptor Agonists (GLP1RAs). StatPearls, StatPearls Publishing."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: Their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Wilbon, S.S., and Kolonin, M.G. (2023). GLP1 Receptor Agonists-Effects beyond Obesity and Diabetes. Cells, 13.","DOI":"10.3390\/cells13010065"},{"key":"ref_12","first-page":"23-0017","article-title":"Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes","volume":"2023","author":"Malavazos","year":"2023","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bjd.12886","article-title":"Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: A prospective case-series study","volume":"171","author":"Buysschaert","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1007\/s00125-011-2232-3","article-title":"Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: Lessons from obesity, diabetes and psoriasis","volume":"54","author":"Hogan","year":"2011","journal-title":"Diabetologia"},{"key":"ref_16","first-page":"1148","article-title":"Efficacy of glucagon-like peptide-1 receptor agonists for psoriasis: An updated systematic review and meta-analysis","volume":"22","author":"Ku","year":"2024","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: Systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ced\/llaf473","article-title":"Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: A 6-month prospective cohort study","volume":"51","author":"Nicolau","year":"2026","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: A randomized-controlled trial","volume":"33","author":"Lin","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_20","first-page":"16527","article-title":"The first case of psoriatic skin lesions exacerbation after liraglutide","volume":"133","author":"Nowowiejska","year":"2023","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_22","first-page":"21-0007","article-title":"Two birds one stone: Semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient","volume":"2021","author":"Costanzo","year":"2021","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Petkovi\u0107-Dabi\u0107, J., Bini\u0107, I., Cari\u0107, B., Bo\u017ei\u0107, L., Umi\u010devi\u0107-\u0160ipka, S., Bednar\u010duk, N., Dabi\u0107, S., \u0160itum, M., Popovi\u0107-Peji\u010di\u0107, S., and Stojiljkovi\u0107, M.P. (2025). Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial. Biomolecules, 15.","DOI":"10.3390\/biom15010046"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Lin, B., Huang, Q., Weng, L., and Lin, L. (2025). Semaglutide in the treatment of a patient with type 2 diabetes mellitus, psoriasis, and metabolic dysfunction-associated steatotic liver disease: A case report. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1684204"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/bjd.12380","article-title":"Liraglutide in combination with acitretin for severe recalcitrant psoriasis","volume":"169","author":"Reid","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1111\/ijd.15863","article-title":"Paradoxical new-onset psoriasiform dermatitis associated with exenatide administration","volume":"61","author":"Bostan","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diabet.2011.11.004","article-title":"Improvement of psoriasis during exenatide treatment in a patient with diabetes","volume":"38","author":"Buysschaert","year":"2012","journal-title":"Diabetes Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jdcr.2026.02.006","article-title":"Psoriasis flare following tirzepatide initiation in a patient with plaque psoriasis in remission: A case report","volume":"71","author":"Oquendo","year":"2026","journal-title":"JAAD Case Rep."},{"key":"ref_29","first-page":"e460","article-title":"Tirzepatide in obese patients with psoriasis on biological therapy: Is this a window of opportunity?","volume":"40","author":"Gisondi","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.25251\/skin.9.3.9","article-title":"GLP1 Receptor Agonist Induced Guttate Psoriasis in an Adult Female","volume":"9","author":"Cook","year":"2025","journal-title":"SKIN J. Cutan. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lebwohl, M., Blauvelt, A., Kartman, C.E., Leatherwood, C., Gordon, K.B., Sattar, N., Puig, L., Merola, J.F., Siu, K., and Wang, R. (2026). Ixekizumab With or Without Tirzepatide in Adults with Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial. JAMA Dermatol.","DOI":"10.1001\/jamadermatol.2026.1753"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Merola, J.F., Mease, P., Kivitz, A., Sattar, N., Coates, L.C., Aletaha, D., Kartman, C.E., Fischer, P., Sun, L., and Mart\u00ednez-Osuna, P. (2026). Ixekizumab with Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults with Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis Rheumatol.","DOI":"10.1002\/art.70134"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.29245\/2767-5157\/2020\/1.1106","article-title":"Remarkable Improvement in Plaque Psoriasis with a 4 week Short Course Liraglutide Therapy in an Obese Type 2 DM Patient","volume":"2","author":"Ramakrishnan","year":"2020","journal-title":"J. Endocrinol. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00592-011-0359-9","article-title":"Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide","volume":"51","author":"Faurschou","year":"2014","journal-title":"Acta Diabetol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1468-3083.2012.04609.x","article-title":"Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: A prospective cohort study","volume":"27","author":"Ahern","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jdv.12629","article-title":"Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients\u2014A randomized placebo-controlled trial","volume":"29","author":"Faurschou","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.medcli.2023.05.021","article-title":"Effects of liraglutide among patients living with psoriasis and obesity","volume":"161","author":"Nicolau","year":"2023","journal-title":"Med. Clin."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.diabres.2019.03.002","article-title":"Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study","volume":"150","author":"Xu","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5126825","DOI":"10.1155\/2023\/5126825","article-title":"The Effect of Clinically Indicated Liraglutide on Pericoronary Adipose Tissue in Type 2 Diabetic Patients","volume":"2023","author":"Biesenbach","year":"2023","journal-title":"Cardiovasc. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/bjd\/ljaf346","article-title":"Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: A large-scale cohort study","volume":"194","author":"Olbrich","year":"2026","journal-title":"Br. J. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.jaad.2025.06.022","article-title":"Glucagon-like peptide-1 receptor agonist use in patients with psoriasis is associated with lower incidence of atherosclerotic cardiovascular disease: A retrospective cohort study using TriNetX","volume":"93","author":"Sontam","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jaad.2025.12.035","article-title":"Glucagon-like peptide-1 receptor agonist therapy in patients with psoriasis is associated with a decreased risk of psoriatic arthritis: A retrospective cohort study using the TriNetX database","volume":"94","author":"Hsiao","year":"2026","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Gao, W., Yu, B., Yan, Y., Zhao, L., and Zhao, R. (2023). Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1151977"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jaad.2007.11.011","article-title":"The effect of weight on the efficacy of biologic therapy in patients with psoriasis","volume":"58","author":"Clark","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Battista, T., Gallo, L., Martora, F., Fattore, D., Potestio, L., Cacciapuoti, S., Scalvenzi, M., and Megna, M. (2024). Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13071940"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5126\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:07:49Z","timestamp":1782907669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":45,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15135126"],"URL":"https:\/\/doi.org\/10.3390\/jcm15135126","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}